Lisa Harding, MD, assistant clinical professor of psychiatry, collaborated extensively since 2022 with Irit Koubi, group product director at Johnson & Johnson, to develop materials highlighting the unique considerations in treating Black patients with esketamine for treatment-resistant depression (TRD).
Recognizing the underrepresentation of Black patients in clinical trials and the importance of addressing health disparities, Harding and Koubi worked to ensure that critical data and insights specific to this population were included.
This material was presented nationally in Houston on February 8, 2025, bringing attention to health care providers the need for equitable and personalized approaches in psychiatric care.
Harding will further present this work at the Black Psychiatrists of America (BPA) 2025 Spring Conference in April, continuing efforts to educate and empower clinicians in optimizing treatment outcomes for Black patients with TRD.